Data for (Study ST003417)
(Analysis AN005616)Values for each metabolite have been scaled by dividing by the mean across all factors Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this studyMetabolite | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 | F12 | F13 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
O-Acetylcarnitine 85 | 0.9633 | 0.8919 | 0.9703 | 0.9834 | 0.9810 | 0.8353 | 1.1132 | 0.9879 | 0.9221 | 0.8218 | 1.4615 | 1.3111 | 0.8786 |
O-Acyl(17:1)carnitine 85 | 1.1864 | 1.4465 | 0.4224 | 0.7103 | 1.4141 | 1.4198 | 0.9085 | 0.7291 | 0.8164 | 1.1289 | 0.8079 | 0.6365 | 1.1866 |
O-Butyrylcarnitine 85 | 1.6642 | 1.8467 | 0.5021 | 0.4240 | 1.5307 | 1.4493 | 0.3004 | 0.2085 | 1.1660 | 1.2063 | 0.1904 | 0.1428 | 1.6843 |
O-Caproylcarnitine 85 | 0.9833 | 1.0331 | 0.7666 | 0.8382 | 0.9517 | 0.9222 | 1.0751 | 0.9958 | 1.0031 | 0.9792 | 1.1902 | 1.1216 | 1.0700 |
O-Caprylcarnitine 85 | 1.0440 | 1.4928 | 1.0041 | 0.4912 | 1.2766 | 1.1794 | 0.8633 | 0.9327 | 1.0228 | 0.9445 | 0.7127 | 0.7360 | 1.1500 |
O-Caprylylcarnitine 85 | 0.9775 | 1.0620 | 0.8815 | 1.0990 | 1.1103 | 0.8317 | 0.9213 | 0.9124 | 1.0582 | 0.8436 | 1.0287 | 0.8112 | 1.2313 |
O-Enanthylcarnitine 85 | 0.8813 | 1.0867 | 0.6515 | 1.1404 | 1.3958 | 0.6555 | 1.1201 | 0.6935 | 0.9535 | 0.5999 | 1.3625 | 1.2810 | 1.0891 |
O-Formyl-L-carnitine 85 | 0.8550 | 1.0992 | 0.5886 | 0.3594 | 1.1618 | 1.0485 | 0.6895 | 1.3351 | 1.6217 | 0.7001 | 1.0775 | 1.1037 | 1.1800 |
O-Lauroleoylcarnitine 85 | 1.1352 | 0.8739 | 1.0743 | 1.0794 | 0.7255 | 1.2830 | 0.9649 | 1.1390 | 1.0311 | 0.9534 | 1.0912 | 0.6779 | 0.9856 |
O-Lauroylcarnitine 85 | 1.5041 | 1.6127 | 0.6714 | 0.3547 | 1.3462 | 1.2924 | 0.5874 | 0.5328 | 1.0519 | 1.1444 | 0.5541 | 0.3655 | 1.4912 |
O-Malonylcarnitine 85 | 0.3576 | 0.3148 | 0.8162 | 0.5876 | 0.3472 | 0.3171 | 1.7414 | 1.2498 | 0.3561 | 0.3128 | 4.6948 | 2.3363 | 0.2841 |
O-Margaroylcarnitine 85 | 1.0283 | 1.5584 | 0.6344 | 0.7699 | 1.4277 | 1.4201 | 0.7535 | 0.6372 | 0.8695 | 1.2522 | 0.5766 | 0.5146 | 1.2789 |
O-Myristoleoylcarnitine 85 | 1.3708 | 1.4371 | 0.5112 | 0.5694 | 1.2585 | 1.4179 | 0.4423 | 0.5653 | 1.2666 | 1.2519 | 0.3025 | 0.5045 | 1.5510 |
O-Myristoylcarnitine 85 | 1.6937 | 2.1646 | 0.2544 | 0.2319 | 1.4844 | 1.6513 | 0.1363 | 0.1402 | 1.0955 | 1.0922 | 0.0796 | 0.0939 | 1.9409 |
O-Oleoylcarnitine 85 | 1.3842 | 1.7699 | 0.4777 | 0.6444 | 1.4102 | 1.4878 | 0.3861 | 0.3487 | 1.1406 | 1.3141 | 0.2013 | 0.3074 | 1.5638 |
O-Palmitoleoylcarnitine 85 | 1.6282 | 1.8733 | 0.4091 | 0.3632 | 1.4216 | 1.5374 | 0.2666 | 0.2436 | 1.2109 | 1.1839 | 0.1757 | 0.2258 | 1.7304 |
O-Palmitoylcarnitine 85 | 1.7122 | 2.0252 | 0.3156 | 0.3330 | 1.4530 | 1.5625 | 0.1689 | 0.1773 | 1.1617 | 1.2464 | 0.1091 | 0.1356 | 1.7998 |
O-Pelargonylcarnitine 85 | 0.9663 | 1.1784 | 0.8596 | 1.1366 | 1.0304 | 0.8043 | 1.1015 | 1.1421 | 0.8484 | 1.1863 | 0.6421 | 0.7726 | 1.1657 |
O-Pentadecyloylcarnitine 85 | 1.5343 | 1.5999 | 0.5167 | 0.6463 | 1.3035 | 1.4402 | 0.5105 | 0.4451 | 1.3085 | 1.0130 | 0.5405 | 0.3855 | 1.3781 |
O-Propionylcarnitine 85 | 0.9811 | 1.1707 | 0.9258 | 0.9175 | 1.0524 | 0.9988 | 0.9920 | 1.0340 | 0.9038 | 1.0415 | 1.0510 | 0.6789 | 1.1262 |
O-Stearoylcarnitine 85 | 1.6248 | 1.5362 | 0.5788 | 0.7426 | 1.3635 | 1.3709 | 0.4344 | 0.5625 | 1.1595 | 1.1796 | 0.3446 | 0.3776 | 1.3624 |
O-Tridecyloylcarnitine 85 | 0.9939 | 0.9343 | 1.0519 | 0.9887 | 1.4471 | 0.8014 | 0.8161 | 0.9511 | 0.9839 | 0.9477 | 1.1556 | 0.5643 | 1.1820 |
O-Undecyloylcarnitine 85 | 0.8696 | 1.2623 | 1.1631 | 1.0831 | 0.9267 | 0.9751 | 1.1023 | 0.7779 | 1.0568 | 1.0419 | 0.7667 | 0.8764 | 1.0490 |
O-Valerylcarnitine 85 | 1.0002 | 1.1839 | 0.8642 | 1.0387 | 1.1045 | 0.8970 | 0.9842 | 0.7805 | 1.1993 | 0.8186 | 0.9009 | 0.9850 | 1.1215 |
Factors:
F1 | Sample source:BT-474 Breast cancer cells | Drug Treatment:1 nM TVB-2640 |
F2 | Sample source:BT-474 Breast cancer cells | Drug Treatment:1 nM TVB-3166 |
F3 | Sample source:BT-474 Breast cancer cells | Drug Treatment:200 nM TVB-2640 |
F4 | Sample source:BT-474 Breast cancer cells | Drug Treatment:200 nM TVB-3166 |
F5 | Sample source:BT-474 Breast cancer cells | Drug Treatment:20 nM TVB-2640 |
F6 | Sample source:BT-474 Breast cancer cells | Drug Treatment:20 nM TVB-3166 |
F7 | Sample source:BT-474 Breast cancer cells | Drug Treatment:500 nM TVB-2640 |
F8 | Sample source:BT-474 Breast cancer cells | Drug Treatment:500 nM TVB-3166 |
F9 | Sample source:BT-474 Breast cancer cells | Drug Treatment:50 nM TVB-2640 |
F10 | Sample source:BT-474 Breast cancer cells | Drug Treatment:50 nM TVB-3166 |
F11 | Sample source:BT-474 Breast cancer cells | Drug Treatment:5 uM TVB-2640 |
F12 | Sample source:BT-474 Breast cancer cells | Drug Treatment:5 uM TVB-3166 |
F13 | Sample source:BT-474 Breast cancer cells | Drug Treatment:Control |